MASTL and triple-negative breast carcinoma: Next, the in vivo antitumor and radiosensitizer activity of MKI-1 was further examined by using the BT549 xenograft mouse model, since a previous report showed that MASTL inhibition is more sensitive to triple-negative breast cancer cells including BT549 (12).